Company Of The Day: Merck

+4.98%
Upside
109
Market
114
Trefis
MRK: Merck logo
MRK
Merck

What?

Merck (NYSE:MRK) and AstraZenica’s cancer drug Lynparza has been approved by the U.S. FDA to treat patients with early-stage breast cancer with certain mutations.

So What?

Relevant Articles
  1. Company Of The Day: Merck
  2. Is A Fall Imminent For Merck Stock After A 12% Rise In A Month?
  3. Will Merck Stock Rise After Its Q3 Results?
  4. Merck Stock Is Likely A Better Pick Over Its Peer
  5. Is Humira Maker A Better Bet Over Merck Stock?
  6. Should You Buy Merck Stock After An Upbeat Q2?

Merck’s alliance revenue from Lynparza stood at about $989 million in 2021, growing 36% year-over-year, making it one of the company’s fastest-growing drugs. It’s likely that the new approval could increase sales further.

See Our Complete Analysis For Merck

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

 Returns Mar 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 MRK Return 2% 2% 33%
 S&P 500 Return -4% -12% 88%
 Trefis MS Portfolio Return -4% -14% 238%

[1] Month-to-date and year-to-date as of 3/14/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates